ERNA Overview

Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

Wall Street analysts forecast ERNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERNA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ernexa Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Ernexa Therapeutics Inc. EPS for the last quarter amounts to -173.80 USD, increased 201.53

Ernexa Therapeutics Inc (ERNA) has 5 emplpoyees as of May 21 2026.

Today ERNA has the market capitalization of 13.30M USD.